Full Press Release Details
terna Zentaris Inc. 1405 du Parc-Technologique Blvd.
Qu bec (Qu bec) Canada G1P 4P5 T 418 652-8525 F 418 652-0881
Aeterna Zentaris Announces At-the-Market Issuance Program
Quebec City, Canada, February 22 , 2011 Aeterna Zentaris Inc. (NASDAQ: AEZS;
TSX: AEZ) (the Company ), a late-stage drug development company specialized in oncology and
endocrinology, announced today that it has filed a prospectus supplement dated February 22, 2011 to
its U.S. shelf prospectus, dated March 12, 2010, forming part of its U.S. registration statement on
Form F-3 with the United States Securities and Exchange Commission ( SEC ) as well as a prospectus
supplement to its Canadian final base shelf prospectus dated March 12, 2010.
Aeterna Zentaris has entered into an At-the-Market ( ATM ) Sales Agreement, dated February 22,
2011, with McNicoll, Lewis Vlak LLC ( MLV ), under which the Company may, at its discretion,
from time to time during the 24-month term of the agreement, sell up to a maximum of 12,500,000 of
its common shares through ATM issuances on the NASDAQ Stock Market not to exceed US$19.8 million,
being the aggregate amount remaining available for distribution under the Company s current F-3
registration statement. MLV will act as sales agent for any sales made under the ATM. The common
shares will be sold at market prices prevailing at the time of a sale (if any) of the common
shares, and, as a result, prices may vary. The Company is not required to sell any of the reserved
shares at any time during the term of the ATM.
The U.S. shelf prospectus and the supplement thereto have been filed with the SEC on the SEC s
website (www.sec.gov) and the Canadian final base shelf prospectus and the supplement thereto have
been filed on the SEDAR website maintained by the Canadian Securities Administrators at
www.sedar.com. Alternatively, MLV will provide copies of the U.S. documents upon request by
contacting McNicoll, Lewis Vlak LLC, Attention: Randy Billhardt, 420 Lexington Avenue, New York,
NY 10170, or by calling 212-580-5881, while copies of the Canadian documents may be obtained by
contacting the Company s Investor Relations department directly by calling (418) 652-8525, ext.
This press release does not and shall not constitute an offer to sell or the solicitation of an
offer to buy any of the common shares, nor shall there be any sale of the common shares in any
state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of such state or jurisdiction.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a late-stage oncology drug development company currently investigating
potential treatments for various cancers including colorectal, ovarian, endometrial cancer and
multiple myeloma. The Company s innovative approach of personalized medicine means tailoring
treatments to a patient s specific condition and to unmet medical needs. Aeterna Zentaris deep
pipeline is drawn from its proprietary discovery unit providing the Company with constant and
long-term access to state-of-the-art therapeutic options. For more information please visit
Investor Relations Coordinator
(418) 652-8525 ext. 265
Director of Communications
(418) 652-8525 ext. 406